Aytu Biopharma Inc
NASDAQ:AYTU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aytu Biopharma Inc
Revenue
Aytu Biopharma Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aytu Biopharma Inc
NASDAQ:AYTU
|
Revenue
$62.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
4%
|
CAGR 10-Years
49%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$96.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$291.6m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-33%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$65.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$72.2B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
Aytu Biopharma Inc
Glance View
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
See Also
What is Aytu Biopharma Inc's Revenue?
Revenue
62.6m
USD
Based on the financial report for Dec 31, 2025, Aytu Biopharma Inc's Revenue amounts to 62.6m USD.
What is Aytu Biopharma Inc's Revenue growth rate?
Revenue CAGR 10Y
49%
Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for Aytu Biopharma Inc have been -16% over the past three years , 4% over the past five years , and 49% over the past ten years .
